Cetrelimab
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively) . Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo[1].
Product Specifications
CAS Number
[2050478-92-5]
Product Name Alternative
JNJ 63723283; JNJ 3283
UNSPSC
12352203
Target
Interleukin Related; PD-1/PD-L1; TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cetrelimab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Cetrelimab]
Molecular Weight
(144.76 kDa)
References & Citations
[1]DeAngelis N, et al. Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models. Cancer Chemother Pharmacol. 2022 Apr;89 (4) :515-527.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
